A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM)
Sponsor: Pfizer
A observational or N/A phase clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2024 — Jul 2024 [monthly]
Completed
-
May 2024 — Jun 2024 [monthly]
Completed
-
May 2023 — May 2024 [monthly]
Completed
▶ Show 2 earlier versions
-
Dec 2022 — May 2023 [monthly]
Completed
Status: Not Yet Recruiting → Completed
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting
First recorded
Oct 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .